Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Gerresheimer AG (GXI.DE)
DE XETRA Healthcare Medical - Instruments & Supplies
Address
Klaus-Bungert-Strasse 4 40468
Düsseldorf, DE
Düsseldorf, DE
CEO
Uwe Ferdinand Röehrhoff
Website
gerresheimer.com
IPO
2007-06-11
ISIN DE000A0LD6E6
Also trades on
Deutsche Börse · GXI.DE (EUR)
Other OTC · GRRMF (USD)
Swiss Exchange · GXI.SW (CHF)
Description
Gerresheimer AG, founded in 1864 and based in Düsseldorf, Germany, is a global supplier specializing in the production and sale of packaging solutions and sophisticated drug delivery systems. The company operates through three distinct divisions. Its Plastics & Devices segment provides a variety of drug administration tools, such as inhalers, insulin pen systems, prefillable syringes, and diagnostic systems, for the pharmaceutical, biotech, diagnostics, and medical technology sectors. This division also manufactures plastic containers, closures, PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and related accessories for solid, liquid, and ophthalmic applications, alongside bottles for nutritional supplements. The Primary Packaging Glass division offers glass primary packaging products for the pharmaceutical and cosmetics industries, including infusion, dropper, and syrup bottles; injection vials, ampoules, and cartridges; and miniature bottles for liquid food, spices, spirits, fragrances, deodorants, skincare, and wellness products. Lastly, the Advanced Technologies division focuses on developing intelligent drug delivery systems, like micro pumps, designed to enable the self-administration of medication for conditions such as Parkinson's disease or heart failure, serving its pharmaceutical and biotech clients.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
242.7K
Beta
0.47
Float Shares
32.05M
Free Float %
92.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.51% | -1.09% | +10.84% | +60.47% | +2.49% | -2.16% | -57.06% | -73.85% | -69.94% | -62.02% | -29.17% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
27.20
DCF (Unlevered)
55.29
+103.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
23% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 5 | 0 |
| Sell | 2 | 0 |
| Strong Sell | 3 | 0 |
Quality scores
Altman Z-Score
0.97
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%+14.0% ★ Q4'25: +12.4% (vs Q4'24)
-
EPS growth Medical - Instruments & Supplies: +16.3%-391.5% Q4'25: -929.9% (vs Q4'24)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-11.0% Q4'25: +3.3% (vs Q4'24)
-
EBIT margin Medical - Instruments & Supplies: +13.5%-9.0% Q4'25: -44.8% (vs Q4'24)
-
ROIC Medical - Instruments & Supplies: +6.0%-8.3% Q4'25: -45.2% (vs Q4'24)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.0% Q4'25: +0.0% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×5.11× Q4'25: 11.42× (vs Q4'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Nov 2007 actual |
Nov 2008 actual |
Nov 2009 actual |
Nov 2010 actual |
Nov 2011 actual |
Nov 2012 actual |
Nov 2013 actual |
Nov 2014 actual |
Nov 2015 actual |
Nov 2016 actual |
Nov 2017 actual |
Nov 2018 actual |
Nov 2019 actual |
Nov 2020 actual |
Nov 2021 actual |
Nov 2022 actual |
Nov 2023 actual |
Nov 2024 actual |
Nov 2025 actual |
Nov 2026 10 Rev. Ana. 7 EPS Ana. |
Nov 2027 11 Rev. Ana. 10 EPS Ana. |
Nov 2028 7 Rev. Ana. 6 EPS Ana. |
Nov 2029 6 Rev. Ana. 2 EPS Ana. |
Nov 2030 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
957.70M
est: 977.90M (-2.1%)
|
1.06B
est: 1.07B (-1.4%)
|
1.00B
est: 1.02B (-1.6%)
|
1.02B
est: 1.04B (-1.4%)
|
1.09B
est: 1.12B (-1.9%)
|
1.22B
est: 1.23B (-1.2%)
|
1.27B
est: 1.30B (-2.4%)
|
1.29B
est: 1.32B (-2.2%)
|
1.38B
est: 1.38B (-0.3%)
|
1.38B
est: 1.38B (-0.5%)
|
1.35B
est: 1.36B (-0.6%)
|
1.37B
est: 1.37B (-0.5%)
|
1.39B
est: 1.42B (-2.1%)
|
1.42B
est: 1.42B (-0.3%)
|
1.50B
est: 1.49B (+0.3%)
|
1.82B
est: 1.78B (+2.0%)
|
1.99B
est: 2.00B (-0.4%)
|
2.04B
est: 2.05B (-0.5%)
|
2.32B
est: 2.31B (+0.5%)
|
2.35B
2.30B – 2.40B
+1.6% YoY
|
2.46B
2.32B – 2.65B
+4.9% YoY
|
2.56B
2.49B – 2.62B
+3.8% YoY
|
2.74B
2.63B – 2.88B
+7.2% YoY
|
2.78B
2.67B – 2.92B
+1.6% YoY
|
| EBITDA |
163.55M
est: 195.12M (-16.2%)
|
172.30M
est: -6.38M (+2,802.6%)
|
176.30M
est: 74.99M (+135.1%)
|
201.79M
est: 95.26M (+111.8%)
|
210.88M
est: 138.16M (+52.6%)
|
229.07M
est: 146.80M (+56.0%)
|
218.70M
est: 197.23M (+10.9%)
|
237.65M
est: 196.67M (+20.8%)
|
265.73M
est: 212.76M (+24.9%)
|
307.78M
est: 251.43M (+22.4%)
|
306.84M
est: 246.96M (+24.2%)
|
274.31M
est: 240.10M (+14.2%)
|
279.55M
est: 277.44M (+0.8%)
|
301.41M
est: 353.66M (-14.8%)
|
293.09M
est: 374.89M (-21.8%)
|
340.20M
est: 392.77M (-13.4%)
|
403.89M
est: 398.82M (+1.3%)
|
405.97M
est: 376.17M (+7.9%)
|
312.91M
est: 424.80M (-26.3%)
|
431.75M
424.00M – 440.71M
+1.6% YoY
|
452.95M
426.45M – 488.40M
+4.9% YoY
|
470.22M
458.76M – 481.68M
+3.8% YoY
|
503.89M
484.36M – 529.22M
+7.2% YoY
|
511.89M
492.06M – 537.63M
+1.6% YoY
|
| EBIT |
65.40M
est: 100.38M (-34.8%)
|
62.90M
est: 58.59M (+7.4%)
|
61.79M
est: 57.76M (+7.0%)
|
95.96M
est: 61.74M (+55.4%)
|
109.85M
est: 101.98M (+7.7%)
|
135.28M
est: 120.82M (+12.0%)
|
135.77M
est: 134.99M (+0.6%)
|
133.39M
est: 135.15M (-1.3%)
|
141.18M
est: 138.19M (+2.2%)
|
181.62M
est: 188.73M (-3.8%)
|
182.02M
est: 170.78M (+6.6%)
|
136.94M
est: 182.74M (-25.1%)
|
122.87M
est: 144.22M (-14.8%)
|
155.88M
est: 126.08M (+23.6%)
|
148.48M
est: 133.65M (+11.1%)
|
168.77M
est: 140.03M (+20.5%)
|
217.86M
est: 205.17M (+6.2%)
|
207.44M
est: 128.04M (+62.0%)
|
-209.32M
est: 144.59M (-244.8%)
|
146.96M
144.32M – 150.01M
+1.6% YoY
|
154.17M
145.15M – 166.24M
+4.9% YoY
|
160.05M
156.15M – 163.95M
+3.8% YoY
|
171.51M
164.87M – 180.13M
+7.2% YoY
|
174.24M
167.48M – 183.00M
+1.6% YoY
|
| Net Income |
837.0K
est: 24.35M (-96.6%)
|
4.51M
est: -1.32M (+441.9%)
|
6.96M
est: 662.8K (+950.4%)
|
46.75M
est: 5.93M (+688.5%)
|
50.50M
est: 46.38M (+8.9%)
|
60.19M
est: 55.82M (+7.8%)
|
62.16M
est: 63.29M (-1.8%)
|
66.34M
est: 63.25M (+4.9%)
|
104.22M
est: 70.57M (+47.7%)
|
121.64M
est: 108.10M (+12.5%)
|
100.89M
est: 115.11M (-12.4%)
|
128.97M
est: 101.97M (+26.5%)
|
80.78M
est: 133.37M (-39.4%)
|
88.56M
est: 82.30M (+7.6%)
|
83.79M
est: 87.24M (-4.0%)
|
96.12M
est: 91.40M (+5.2%)
|
116.13M
est: 117.09M (-0.8%)
|
109.72M
est: 154.06M (-28.8%)
|
-320.32M
est: 3.36M (-9,640.0%)
|
56.94M
28.14M – 100.30M
+1,596.0% YoY
|
84.85M
54.13M – 149.81M
+49.0% YoY
|
110.64M
109.65M – 176.08M
+30.4% YoY
|
176.23M
167.35M – 187.74M
+59.3% YoY
|
161.02M
152.91M – 171.55M
-8.6% YoY
|
| SGA |
164.65M
est: 163.01M (+1.0%)
|
207.04M
est: 180.92M (+14.4%)
|
196.81M
est: 169.48M (+16.1%)
|
207.93M
est: 201.15M (+3.4%)
|
212.62M
est: 223.18M (-4.7%)
|
220.77M
est: 235.01M (-6.1%)
|
231.16M
est: 210.48M (+9.8%)
|
222.11M
est: 218.33M (+1.7%)
|
242.79M
est: 234.84M (+3.4%)
|
255.37M
est: 228.23M (+11.9%)
|
255.57M
est: 234.65M (+8.9%)
|
224.07M
est: 215.42M (+4.0%)
|
233.30M
est: 229.03M (+1.9%)
|
236.99M
est: 237.66M (-0.3%)
|
250.34M
est: 251.92M (-0.6%)
|
304.64M
est: 263.94M (+15.4%)
|
326.02M
est: 333.19M (-2.2%)
|
341.74M
est: 322.27M (+6.0%)
|
438.67M
est: 394.98M (+11.1%)
|
401.44M
394.24M – 409.77M
+1.6% YoY
|
421.15M
396.51M – 454.11M
+4.9% YoY
|
437.21M
426.56M – 447.86M
+3.8% YoY
|
468.52M
450.36M – 492.07M
+7.2% YoY
|
475.96M
457.51M – 499.89M
+1.6% YoY
|
| EPS |
-0.04
est: 0.70 (-105.5%)
|
0.02
est: 2.00 (-99.0%)
|
0.18
est: 1.27 (-85.9%)
|
1.38
est: 1.97 (-30.1%)
|
1.61
est: 2.30 (-29.9%)
|
1.98
est: 2.46 (-19.6%)
|
1.98
est: 2.68 (-26.1%)
|
2.11
est: 2.86 (-26.2%)
|
3.32
est: 3.26 (+1.8%)
|
3.87
est: 4.19 (-7.6%)
|
3.21
est: 4.04 (-20.5%)
|
4.11
est: 4.55 (-9.6%)
|
2.57
est: 4.73 (-45.6%)
|
2.82
est: 3.93 (-28.3%)
|
2.67
est: 4.07 (-34.4%)
|
3.06
est: 4.20 (-27.1%)
|
3.48
est: 3.43 (+1.4%)
|
3.18
est: 4.43 (-28.1%)
|
-9.27
est: 2.37 (-490.6%)
|
2.21
0.81 – 2.90
-6.7% YoY
|
3.16
1.57 – 4.34
+42.5% YoY
|
3.95
3.17 – 5.10
+25.2% YoY
|
5.10
4.84 – 5.43
+29.1% YoY
|
4.66
4.43 – 4.96
-8.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-25 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-243.56M
OE per share TTM
-7.05
Owner's Yield
-25.92%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
59.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 77 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF Dist MMS.PA | 0.22% | 1.56M | 0.40% |
| 2 | UBS MSCI EMU Small Cap UCITS ETF EUR dis UEFD.DE | 0.16% | 1.20M | 0.33% |
| 3 | iShares MSCI EMU Small Cap UCITS ETF CES1.L | 0.16% | 1.63M | 0.58% |
| 4 | State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR Acc ZPRX.DE | 0.15% | 1.20M | 0.30% |
| 5 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.07% | 232.8K | 0.23% |
| 6 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.07% | 232.8K | 0.23% |
| 7 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.07% | 2.30M | 0.30% |
| 8 | iShares MSCI Europe Small-Cap ETF IEUS | 0.06% | 109.7K | 0.41% |
| 9 | Vanguard Germany All Cap UCITS ETF (EUR) Distributing VGER.DE | 0.05% | 145.3K | 0.07% |
| 10 | Schwab International Small-Cap Equity ETF SCHC | 0.04% | 2.12M | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-15.4K
Shares Outstanding
34.54M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Uwe Ferdinand Röehrhoff | Chairman of the Management Board & CEO | 2M | male |
| Achim Schalk | Member of the Management Board | 1M | male |
| Wolf Uwe Lehmann | Chief Financial Officer & Member of the Management Board | 1M | male |
| Katja Schnitzler | Global Senior Vice President of People & Organization and Member of Supervisory Board | 110.0K | female |
| Hans-Norbert Topp | Head of Moulded Glass Business Unit | — | male |
| Ueli Utzinger | Group Senior Director Marketing & Communication | — | — |
| Guido Pickert | Head of Investor Relations | — | male |
| Carolin Nadilo | Corporate Director of Investor Relations | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GXI.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
